Navigation Links
Budesonide in Medical News

MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca

MOUNTAIN VIEW, Calif., Feb. 3 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced that the waiting period under the Hart-Scott-Rodino Act for its Unit Dose Budesonide (UDB) worldwide agreement with AstraZeneca has expired, and the agreement is now effective. Under...

Par Pharmaceutical Begins Shipment of Budesonide Inhalation Suspension Immediately

WOODCLIFF LAKE, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX ) today announced that it has entered into a supply and distribution agreement with AstraZeneca in the U.S. to market budesonide inhalation suspension, which is a generic form of AstraZeneca's P...

PARI Respiratory Releases Results of Study Comparing Nebulizers Delivering Budesonide at CHEST 2008

MIDLOTHIAN, Va., Oct. 28 /PRNewswire/ -- Today, PARI Respiratory Equipment presented a comparative study of three commercially available, breath-enhanced nebulizers and their in-vitro performance and delivery efficiency of budesonide inhalation suspension (Pulmicort Respules, AstraZeneca). Con...

Addition Of Budesonide To Formoterol Reduces Risk Of Mortality

For severe COPD patients treated with budesonide added to either formoterol (Symbicort, AstraZeneca) and/or a short acting bronchodilator, there is a reduced risk of mortality// compared to patients treated with only formoterol and/or terbutaline Important new data from the analysis of combi...

MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results

... and Chief Executive Officer of MAP Pharmaceuticals. "With these positive results in hand and our recent decision to suspend development of Unit Dose budesonide (UDB), we are now focusing our efforts on the development of LEVADEX. We believe that LEVADEX has a differentiated profile, with the potential to pro...

MAP Pharmaceuticals Announces Termination of Pediatric Asthma Collaboration

...aq: MAPP ) today announced that it has received a notice of termination of the license agreement with AstraZeneca related to the company's Unit Dose budesonide (UDB) product candidate. The termination was received on July 8, 2009, effective immediately. All rights licensed to AstraZeneca in the agreement no...

MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints

...ns that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical development. Unit Dose budesonide is being developed in collaboration with AstraZeneca for the potential treatment of asthma in children, and LEVADEX inhaled therapy is being developed...

MAP Pharmaceuticals Announces Presentations at the American Thoracic Society International Conference

...hat it will present three posters on its Unit Dose budesonide (UDB) pediatric asthma therapy clinical program an...ntations are titled: "Unit Dose budesonide (UDB): A New Submicron Dispersion of Nebulizable budesonide Studied in 360 Children 12 Months to 8 Years Old w...

MAP Pharmaceuticals to Present at the Deutsche Bank Securities 34th Annual Health Care Conference

...ns that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical development. Unit Dose budesonide is being developed in collaboration with AstraZeneca for the potential treatment of asthma in children, and MAP0004 is being developed for the potenti...

Santarus to Webcast Analyst Day and Investor Briefing Presentation on May 13

... European Crohn's and Colitis Organization budesonide MMX (R) - Clinical Development Program in Ulcerat...loping two late-stage lower GI product candidates, budesonide MMX(R) and rifamycin SV MMX(R) for the U.S. market. budesonide MMX is being investigated in two multi-center Phas...
Budesonide in Medical Technology

MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints

MOUNTAIN VIEW, Calif., Feb. 23 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) announced today results of its initial Phase 3 clinical trial of Unit Dose Budesonide (UDB) for the potential treatment of children with asthma. The Company announced that the clinical trial d...

AstraZeneca's Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints

LONDON, Feb. 23 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. announced today that its initial Phase 3 clinical trial of Unit Dose Budesonide (UDB) for the potential treatment of children with asthma did not meet its co-primary endpoints: asthma control as assessed by changes from baseline i...

Meritage Pharma Initiates Phase 2b Clinical Trial of Oral Viscous Budesonide for Pediatric Patients With Eosinophilic Esophagitis

SAN DIEGO, Jan. 22 /PRNewswire/ -- Meritage Pharma, Inc. announced today that it has initiated a dose-ranging Phase 2b clinical trial to evaluate oral viscous budesonide (OVB) for the treatment of children and adolescents with eosinophilic esophagitis (EoE), an allergic inflammatory condition of t...

MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2 Clinical Data at the World Asthma Meeting

MOUNTAIN VIEW, Calif., June 22, 2007 /PRNewswire/ -- MAP Pharmaceuticals, Inc. today announced that it will present Phase 2 data from its Unit Dose Budesonide (UDB) pediatric asthma therapy clinical program at the World Asthma Meeting at the Lutfi Kirdar Convention and Exhibition Center in Istanbu...

Pivotal Data Showed SYMBICORT(R) Improved Lung Function in Adults with COPD

...c Obstructive Pulmonary Disease (COPD) relative to budesonide and formotorol administered alone, and placebo.(1,...V1 within 15 minutes with SYMBICORT as compared to budesonide and placebo on the day of randomization and end of...0/4.5 micrograms (mcg), SYMBICORT pMDI 80/4.5 mcg, budesonide pMDI 160 mcg + formoterol DPI 4.5 mcg,...

Newly Released Data on Onset of Effect and Patient Perception With SYMBICORT in Adults With Asthma

...omization (median time, 13 minutes), compared with budesonide pMDI and placebo (P<.001).(1) Time to onset of cli...atients receiving SYMBICORT versus those receiving budesonide pMDI and placebo reported feeling their study medi...ication begin to work (except for SYMBICORT versus budesonide pMDI in Study 1 [P=.073]).(1) The results seen at ...

MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion

...izing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates in Phase 3 clinical trials. Unit Dose budesonide is being developed for the potential treatment of pediatric asthma, and MAP0004 is being developed for the potential treatment of migraine. MAP Pharma...

MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine

...izing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates in Phase 3 clinical trials. Unit Dose budesonide is being developed for the potential treatment of pediatric asthma, and MAP0004 is being developed for the potential treatment of migraine. MAP Pharma...

Study Analyzed SYMBICORT(R) in Children with Persistent Asthma

...hose taking formoterol dry powder inhaler (DPI) or budesonide pressurized metered-dose inhaler (pMDI). Results w...ations and received two inhalations twice-daily of budesonide pMDI 40 micrograms (mcg), 128 patients(1,2) were r...s twice-daily, 145(1,2) were randomized to receive budesonide pMDI 40 mcg two inhalations twice-daily, and 138(1...

AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication

...ompared with formoterol 4.5 and in average post-dose FEV1 compared with budesonide 160, with maintenance of effect for both comparisons over the 6-month t...x 160/4.5 microgram & 80/4.5 microgram bid Compared to Formoterol TBH, budesonide pMDI (& the combination) & Placebo in COPD Patients. [CLINICAL STUDY R...
Budesonide in Biological News

Pregnant women with asthma can be more confident about some medicines

... budesonide sprays can be regarded as safe for pregnancy - oth...ma drugs they were using before they got pregnant. budesonide sprays are the best studied and can be regarded as...ed in trials that include pregnant women. However, budesonide sprays have been studied enough: women can be conf...
Budesonide in Biological Technology

Par Pharmaceutical Halts Shipment of Budesonide Inhalation Suspension

WOODCLIFF LAKE, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX ) today announced that the U.S. District Court for the District of New Jersey last night granted AstraZeneca Pharmaceuticals' motion for a temporary restraining order (TRO) halting sales of Teva...

PARI Respiratory to Present New Study Comparing Nebulizers Delivering Budesonide at CHEST 2008

MIDLOTHIAN, Va., Oct. 22 /PRNewswire/ -- At CHEST 2008, PARI Respiratory Equipment will present a comparative study of three commercially available, breath-enhanced nebulizers and their in-vitro performance and delivery efficiency of budesonide inhalation suspension (Pulmicort Respules, AstraZ...

Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R)

... by a three month follow up period. Full results will be presented at the World Congress of Nephrology 2009, 22-26 May in Milan (Smerud et al, Enteric budesonide Ameliorates Albuminuria and Glomerular Filtration Rate in IgA Nephropathy Patients) and at the satellite meeting, IgA Nephropathy, 26-28 May in Stresa...

FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD)

...ts using SYMBICORT had significantly greater mean improvements from baseline in 1-hour post-dose FEV1 averaged over the treatment period compared with budesonide 160 mcg and placebo.(2) Furthermore, the median time to onset of significant bronchodilation (greater than or equal to 15% improvement in FEV1) was fi...

MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine

...ditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical trials. Unit Dose budesonide is being developed for the potential treatment of asthma in children, and MAP0004 is being developed for the potential treatment of migraine. MAP Phar...

MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs

...ounced continued progress with its two Phase 3 clinical programs, Unit Dose budesonide (UDB) for children with asthma and MAP0004 for the acute treatment of migra...he company has two product candidates in Phase 3 clinical trials. Unit Dose budesonide is being developed for the potential treatment of asthma in children, and M...

Pediatric Asthma Programs Featuring PARI Pharma's eFlow Acquired by AstraZeneca

...w is featured prominently in the development pipeline. Included in the AstraZeneca acquisition are the North American rights to a Captisol(R) enabled budesonide solution (controller medication), a proprietary short-acting beta-agonist solution (rescue medication), a customized version of eFlow(R) (novel aeroso...
Other Tags
(Date:10/1/2014)... First Warning Systems, a pioneer in early cancer ... body, announced the company is changing its name to ... of upcoming product releases. The initial focus will be ... initial focus will be an ‘Internet of Everthing,’ wearable ... changes over time,” said Rob Royea, president and CEO ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Farmington ... including a redefined mission and visual identity helping ... of partnering with them to create greater benefit ... brand that focuses on empowering customers to better ... , The crown jewel of the rebrand is ...
(Date:10/1/2014)... Beverly Hills licensed Clinical Psychologist and nationally ... years of private practice in her Beverly Hills office ... greater joy and fulfillment in their relationships. Dr. Mojas ... suggestions for anyone who suspects they are in a ... or not, it’s not always easy to know when ...
(Date:10/1/2014)... City, NJ (PRWEB) October 01, 2014 Diet ... with their intentions to lose weight and their dieting attempts ... unhealthy, fatty foods. Including hormone diet treatments into ... only allows patients to see fast and effective weight loss ... and begin forming healthy habits to maintain their weight for ...
(Date:10/1/2014)... 01, 2014 Scientists at the University ... that target immune system proteins has the power to ... posted details of the new study on their website. ... , Researchers in the UWA School of Pathology and ... to mice with mesothelioma with promising results. , ...
Breaking Medicine News(10 mins):Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2
(Date:9/30/2014)... have in common? Unlike most eukaryotic multicellular organisms ... these organisms are all polyploid, meaning they have three ... 3 and 4 sets of chromosomes, respectively, and strawberries ... fact most plant species are polyploid. Polyploidy, or genome ... only recently, with the development of molecular tools, has ...
(Date:9/30/2014)... drinking water may increase the risk of stillbirth ... led by a Boston University School of Public ... journal Environmental Health , compared 1,091 PCE-exposed ... in Cape Cod, Ma., where water was contaminated ... by the installation of vinyl-lined asbestos cement pipes. ...
(Date:9/30/2014)... comes to using marijuana, new research, involving mice and ... Journal of Leukocyte Biology , suggests that ... you should. That,s because a team of Italian scientists ... serious long-term damage to the immune system. This damage ... such as multiple sclerosis, inflammatory bowel disease and rheumatoid ...
Breaking Biology News(10 mins):Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 3Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 4Contaminated water linked to pregnancy complications, BU study finds 2Adolescent exposure to thc may cause immune systems to go up in smoke 2
Other Contents